LB Pharmaceuticals Statistics
Total Valuation
LBRX has a market cap or net worth of $915.36 million. The enterprise value is $553.19 million.
Important Dates
The next estimated earnings date is Monday, August 10, 2026, before market open.
| Earnings Date | Aug 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
LBRX has 28.68 million shares outstanding. The number of shares has increased by 4,085.30% in one year.
| Current Share Class | 28.68M |
| Shares Outstanding | 28.68M |
| Shares Change (YoY) | +4,085.30% |
| Shares Change (QoQ) | +11.16% |
| Owned by Insiders (%) | 0.82% |
| Owned by Institutions (%) | 71.91% |
| Float | 18.10M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.42 |
| P/TBV Ratio | 2.42 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 35.68, with a Debt / Equity ratio of 0.01.
| Current Ratio | 35.68 |
| Quick Ratio | 33.53 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -19.55% and return on invested capital (ROIC) is -13.89%.
| Return on Equity (ROE) | -19.55% |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | -13.89% |
| Return on Capital Employed (ROCE) | -11.78% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.11M |
| Employee Count | 35 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, LBRX has paid $1,000 in taxes.
| Income Tax | 1,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 29.91 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 65.35 |
| Average Volume (20 Days) | 316,962 |
Short Selling Information
The latest short interest is 4.02 million, so 14.00% of the outstanding shares have been sold short.
| Short Interest | 4.02M |
| Short Previous Month | 4.02M |
| Short % of Shares Out | 14.00% |
| Short % of Float | 22.18% |
| Short Ratio (days to cover) | 25.86 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -45.08M |
| Pretax Income | -38.95M |
| Net Income | -38.95M |
| EBITDA | -44.76M |
| EBIT | -45.08M |
| Earnings Per Share (EPS) | -$2.59 |
Full Income StatementBalance Sheet
The company has $365.64 million in cash and $3.47 million in debt, giving a net cash position of $362.17 million or $12.63 per share.
| Cash & Cash Equivalents | 365.64M |
| Total Debt | 3.47M |
| Net Cash | 362.17M |
| Net Cash Per Share | $12.63 |
| Equity (Book Value) | 378.69M |
| Book Value Per Share | 13.21 |
| Working Capital | 378.17M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$50.37 million and capital expenditures -$63,000, giving a free cash flow of -$50.43 million.
| Operating Cash Flow | -50.37M |
| Capital Expenditures | -63,000 |
| Depreciation & Amortization | 324,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -50.43M |
| FCF Per Share | -$1.76 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |